Array Biopharma (Call) (ARRY) Shareholder Venbio Select Advisor Lowered Stake by $850,000 as Market Value Rose; Nucor (Call) (NUE) Shareholder Peak6 Investments LP Boosted Its Position by $9.94 Million as Share Price Declined

May 18, 2018 - By Migdalia James

Nucor Corporation (NYSE:NUE) Logo

Matthew Hulsizer increased its stake in Nucor Corp (Call) (NUE) by 85.39% based on its latest 2017Q4 regulatory filing with the SEC. Peak6 Investments Lp bought 157,800 shares as the company’s stock declined 6.71% with the market. The hedge fund run by Matthew Hulsizer held 342,600 shares of the steel and iron ore company at the end of 2017Q4, valued at $21.78M, up from 184,800 at the end of the previous reported quarter. Peak6 Investments Lp who had been investing in Nucor Corp (Call) for a number of months, seems to be bullish on the $20.92B market cap company. The stock increased 1.20% or $0.78 during the last trading session, reaching $65.76. About 2.82M shares traded or 10.90% up from the average. Nucor Corporation (NYSE:NUE) has risen 1.23% since May 18, 2017 and is uptrending. It has underperformed by 10.32% the S&P500.

Venbio Select Advisor Llc decreased its stake in Array Biopharma Inc (Call) (ARRY) by 85% based on its latest 2017Q4 regulatory filing with the SEC. Venbio Select Advisor Llc sold 425,000 shares as the company’s stock rose 29.01% while stock markets declined. The institutional investor held 75,000 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $216,000, down from 500,000 at the end of the previous reported quarter. Venbio Select Advisor Llc who had been investing in Array Biopharma Inc (Call) for a number of months, seems to be less bullish one the $3.27B market cap company. The stock increased 1.29% or $0.2 during the last trading session, reaching $15.75. About 1.48M shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 68.58% since May 18, 2017 and is uptrending. It has outperformed by 57.03% the S&P500.

Since February 13, 2018, it had 0 insider purchases, and 6 insider sales for $7.08 million activity. The insider HALL LADD R sold $2.66 million. 8,000 Nucor Corporation (NYSE:NUE) shares with value of $520,880 were sold by NAPOLITAN RAYMOND S JR. On Tuesday, February 13 FERRIOLA JOHN J sold $917,719 worth of Nucor Corporation (NYSE:NUE) or 14,313 shares. Frias James D sold $2.67 million worth of Nucor Corporation (NYSE:NUE) on Monday, February 19.

Investors sentiment increased to 0.93 in 2017 Q4. Its up 0.04, from 0.89 in 2017Q3. It is positive, as 53 investors sold NUE shares while 231 reduced holdings. 92 funds opened positions while 173 raised stakes. 244.43 million shares or 5.15% more from 232.46 million shares in 2017Q3 were reported. Grassi Investment Mgmt owns 0.8% invested in Nucor Corporation (NYSE:NUE) for 77,300 shares. Moreover, Catawba Cap Mngmt Va has 0.76% invested in Nucor Corporation (NYSE:NUE) for 52,611 shares. Adirondack Trust, a New York-based fund reported 2,040 shares. Bank Of Nova Scotia owns 229,817 shares. Hellman Jordan Mgmt Com Ma reported 4,100 shares stake. California-based Bender Robert Associate has invested 0.19% in Nucor Corporation (NYSE:NUE). Landscape Capital Mgmt Limited Liability Co holds 0.14% or 24,718 shares. Twin Cap Management reported 67,550 shares. Bancorp Of America De holds 0.04% or 3.88M shares. Carlton Hofferkamp Jenks Wealth Mngmt Ltd Com accumulated 10,704 shares or 0.43% of the stock. Farmers Trust holds 1.26% in Nucor Corporation (NYSE:NUE) or 67,055 shares. Barclays Plc, a United Kingdom-based fund reported 317,580 shares. Parallax Volatility Advisers L P, California-based fund reported 7,440 shares. Endurance Wealth Incorporated owns 500 shares. Amer Group Inc has invested 0.03% of its portfolio in Nucor Corporation (NYSE:NUE).

Among 21 analysts covering Nucor Corporation (NYSE:NUE), 14 have Buy rating, 0 Sell and 7 Hold. Therefore 67% are positive. Nucor Corporation had 84 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Barclays Capital on Monday, February 6. The firm earned “Hold” rating on Wednesday, March 23 by Deutsche Bank. The firm earned “Buy” rating on Wednesday, November 2 by Berenberg. The firm has “Hold” rating given on Friday, September 22 by Cowen & Co. Barclays Capital maintained it with “Overweight” rating and $50 target in Monday, October 5 report. The company was maintained on Thursday, September 28 by Credit Suisse. The firm has “Equal-Weight” rating given on Tuesday, February 6 by Morgan Stanley. The stock of Nucor Corporation (NYSE:NUE) has “Hold” rating given on Thursday, January 4 by Cowen & Co. Berenberg upgraded the shares of NUE in report on Tuesday, December 6 to “Buy” rating. The firm has “Hold” rating by BMO Capital Markets given on Tuesday, January 30.

Peak6 Investments Lp, which manages about $21.48B US Long portfolio, decreased its stake in Agco Corp (Call) (NYSE:AGCO) by 17,600 shares to 26,500 shares, valued at $1.89M in 2017Q4, according to the filing. It also reduced its holding in British Amern Tob Plc (Call) (NYSEMKT:BTI) by 11,700 shares in the quarter, leaving it with 36,600 shares, and cut its stake in Applied Optoelectronics Inc (Call) (NASDAQ:AAOI).

More news for Nucor Corporation (NYSE:NUE) were recently published by: Seekingalpha.com, which released: “Nucor Sees Further Growth Acceleration” on April 23, 2018. Streetinsider.com‘s article titled: “Macquarie Upgrades Nucor (NUE) to Outperform” and published on May 17, 2018 is yet another important article.

Investors sentiment increased to 1.3 in Q4 2017. Its up 0.09, from 1.21 in 2017Q3. It increased, as 20 investors sold ARRY shares while 50 reduced holdings. 27 funds opened positions while 64 raised stakes. 194.11 million shares or 1.73% more from 190.80 million shares in 2017Q3 were reported. Hollencrest Management accumulated 141,470 shares. Jefferies Grp Inc Limited Company has 14,475 shares. 2.44 million were reported by Wells Fargo And Mn. Aperio Ltd Company invested 0% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Venbio Select Advisor Ltd has invested 4.54% in Array BioPharma Inc. (NASDAQ:ARRY). Millennium Management Ltd Liability Com invested 0.05% in Array BioPharma Inc. (NASDAQ:ARRY). First Advsrs LP reported 138,405 shares. 3.68 million were reported by Morgan Stanley. California Employees Retirement Sys reported 0% stake. Moreover, Citadel Advisors Limited Liability has 0.01% invested in Array BioPharma Inc. (NASDAQ:ARRY). State Of Wisconsin Investment Board holds 0.01% or 169,100 shares in its portfolio. Pinnacle Associates Ltd reported 2.72M shares or 0.67% of all its holdings. Prudential Financial Inc has invested 0% in Array BioPharma Inc. (NASDAQ:ARRY). Ubs Asset Management Americas has invested 0.02% in Array BioPharma Inc. (NASDAQ:ARRY). Credit Suisse Ag holds 214,332 shares.

Analysts await Array BioPharma Inc. (NASDAQ:ARRY) to report earnings on August, 8. They expect $-0.25 earnings per share, down 47.06% or $0.08 from last year’s $-0.17 per share. After $-0.11 actual earnings per share reported by Array BioPharma Inc. for the previous quarter, Wall Street now forecasts 127.27% negative EPS growth.

Venbio Select Advisor Llc, which manages about $380.08M and $1.54 billion US Long portfolio, upped its stake in Argenx Se by 375,275 shares to 804,875 shares, valued at $50.82M in 2017Q4, according to the filing. It also increased its holding in Mirati Therapeutics Inc (NASDAQ:MRTX) by 687,500 shares in the quarter, for a total of 4.40M shares, and has risen its stake in Cascadian Therapeutics Inc.

Since December 16, 2017, it had 0 insider buys, and 9 sales for $16.27 million activity. Sandor Victor sold $2.76M worth of Array BioPharma Inc. (NASDAQ:ARRY) on Friday, March 9. Robbins Andrew R sold $3.03 million worth of stock or 282,874 shares. Haddock Jason had sold 7,500 shares worth $102,975 on Tuesday, January 16. On Saturday, December 16 Squarer Ron sold $8.90M worth of Array BioPharma Inc. (NASDAQ:ARRY) or 819,671 shares.

More news for Array BioPharma Inc. (NASDAQ:ARRY) were recently published by: Streetinsider.com, which released: “Array Biopharma (ARRY) Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination …” on May 16, 2018. Profitconfidential.com‘s article titled: “ARRY Stock Is Now Primed for a Move Toward Higher Prices” and published on May 14, 2018 is yet another important article.

Among 10 analysts covering Array BioPharma (NASDAQ:ARRY), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Array BioPharma had 38 analyst reports since June 3, 2016 according to SRatingsIntel. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Thursday, May 10 by Cowen & Co. The rating was maintained by Stifel Nicolaus with “Buy” on Sunday, January 21. Jefferies maintained Array BioPharma Inc. (NASDAQ:ARRY) on Monday, June 12 with “Buy” rating. The firm earned “Outperform” rating on Monday, September 26 by Leerink Swann. The rating was maintained by Cantor Fitzgerald on Wednesday, August 9 with “Buy”. The company was initiated on Friday, June 3 by Suntrust Robinson. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, November 29. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Overweight” rating by Piper Jaffray on Monday, September 26. The stock has “Neutral” rating by JP Morgan on Friday, February 3. The firm has “Buy” rating by Cowen & Co given on Tuesday, October 31.

Nucor Corporation (NYSE:NUE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts